Shots:

• The P-III GENESIS Trial involves assessing of BL-8040 + G-CSF (granulocyte colony-stimulating factor) vs G-CSF/PBO in 177 patients with multiple myeloma for the mobilization of CD34 HSCs for autologous transplantation across 25 centres
• The study resulted in meeting 1EP with 82% patients reached threshold ≥ 6x106 CD34 cells/kg in 2 apheresis sessions- 64% reached threshold ≥ 6x106 CD34 cells/kg in single apheresis- successful engraftment with BL-8040 mobilized HSCs was observed
• BL-8040 is a cancer therapy leading to mobilization of HSCs into the peripheral blood targeted for the treatment of hematological malignancies and solid tumors. BioLineRx in-licensed BL-8040 from Biokine Therapeutics and was developed with the name BKT-140

  Ref: BiolineRx | Image: WJH